Nano-targeted Delivery of Rad6/Translesion Synthesis Inhibitor for Triple Negative Breast Cancer Therapy

The triple negative breast cancer (TNBC) subtype regardless of their BRCA1 status has the poorest outcome compared to other breast cancer subtypes and currently there are no approved targeted therapies for TNBC. We have previously demonstrated the importance of Rad6-mediated translesion synthesis pa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Cancer Ther
Egile Nagusiak: Saadat, Nadia, Liu, Fangchao, Haynes, Brittany, Nangia-Makker, Pratima, Bao, Xun, Li, Jing, Polin, Lisa, Gupta, Smiti, Mao, Guangzhao, Shekhar, Malathy P
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279467/
https://ncbi.nlm.nih.gov/pubmed/30242094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0364
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak